AMPEL BioSolutions: Funding, Investors & Team (Sep 2026)

AMPEL BioSolutions is a precision medicine company with a pipeline of CLIA-certified gene expression tests for blood or tissue samples that provides decision support by determining disease status, identifying molecular pathways, and predicting drug options. Genomic platforms, bioinformatics, RNA analytics, and ML/AI algorithms are covered by patents and are disease-agnostic. AMPEL BioSolutions was founded to bring personalized precision medicine to patients with immune system and inflammation diseases. In 2022, AMPEL expects to commercialize its first product, a CLIA-certified blood test for lupus patients/physicians called LuGENE that assesses disease state/flares and best drug option(s). AMPEL's technology covers over 95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test. AMPEL's exclusive curated database of >10,000 Lupus patient gene expression profiles with rich clinical information is the world's largest and fuels machine learning predictions based on evidence. AMPEL's customers are Pharma/Biotech, utilizing its proprietary genomic platform, bioinformatic tools, and ML/AI algorithms for clinical trial design, management, and patient stratification.

AMPEL BioSolutions has raised $2.9M across 2 rounds on record. The most recent is an undisclosed round of $1.8M announced in Jul 2023.

AMPEL BioSolutions' most recent funding round on record is an undisclosed round of $1.8M, announced in Jul 2023.

FundedIQ lists Amrie Grammer (Founder) at AMPEL BioSolutions.

AMPEL BioSolutions is based in Charlottesville, Virginia, United States.

AMPEL BioSolutions is in the 11-50 employee band.

AMPEL BioSolutions' latest round of $1.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.